Rebamipide with Proton Pump Inhibitors (PPIs) versus PPIs Alone for the Treatment of Endoscopic Submucosal Dissection-Induced Ulcers: A Meta-analysis

Table 1

Characteristics of the included trials.

Authors	Year	Country	Mean age (years) E:C	No. of patients E:C	Male E:C	Interventions E:C		Duration (weeks)
Kato et al. [11]	2010	Japan	73/73	31/31	20/24	PPIs + 100 mg rebamipide 3 times/day	Rabeprazole 10 mg/day	4
Fujiwara et al. [15]	2011	Japan	68/69	30/31	21/24	PPIs + rebamipide 300 mg/day	Omeprazole 20 mg/day	8
Araki et al. [16]	2012	Japan	71/69.5	45/42	30/30	PPIs + 100 mg rebamipide 3 times/day	Omeprazole 20 mg/day, rabeprazole 10 mg/day, or lansoprazole 30 mg/day	4
Kobayashi et al. [17]	2012	Japan	70.0/70.8	85/85	66/68	PPIs + rebamipide 300 mg/day	Omeprazole 20 mg/day or lansoprazole 30 mg/day	4–6
Shin et al. [18]	2012	Korea	63.4/64.9	126/129	101/98	PPIs + 100 mg rebamipide 3 times/day	Pantoprazole 40 mg/day	4
Takayama et al. [9]	2013	Japan	67/70	45/44	31/36	Lansoprazole 30 mg/day, 5 d; then rebamipide 300 mg/day	Lansoprazole 30 mg/day	8
Nakamura et al. [19]	2015	Japan	68/67	33/34	27/28	PPIs + rebamipide 300 mg/day	Rabeprazole 20 mg/day	8
Nakamura et al. [20]	2016	Japan	68.7/70.3	54/55	NP	PPIs + 100 mg rebamipide 3 times/day	Rabeprazole 10 mg/day	8
Yan et al. [21]	2019	China	59.80/59.95	137/133	103/106	PPIs + 100 mg rebamipide 3 times/day	Lansoprazole 30 mg/day + placebo 3 times/day	8

PPIs: proton pump inhibitors; E: treatment group with rebamipide; C: treatment group without rebamipide; NP: not provided.